--- title: "Clover Health Investments | 8-K: FY2026 Q2 Revenue: USD 743.17 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295048007.md" datetime: "2026-08-06T03:10:32.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295048007.md) - [en](https://longbridge.com/en/news/295048007.md) - [zh-HK](https://longbridge.com/zh-HK/news/295048007.md) generator: "portal-rs" --- # Clover Health Investments | 8-K: FY2026 Q2 Revenue: USD 743.17 M Revenue: As of FY2026 Q2, the actual value is USD 743.17 M. EPS: As of FY2026 Q2, the actual value is USD 0.05. EBIT: As of FY2026 Q2, the actual value is USD 28 M. ### Second Quarter 2026 Financial Highlights Clover Health Investments, Corp. reported a GAAP Net Income of $28 million for the second quarter of 2026, a significant improvement from a net loss of - $10.6 million in the prior year period. Consolidated Gross Profit for the quarter was $153 million, marking a 53.6% increase year-over-year from $99.6 million. Adjusted EBITDA increased by 139.2% to $40.9 million, compared to $17.1 million in the second quarter of 2025. Adjusted Net income also saw a substantial rise, reaching $40.4 million, up 141.9% from $16.7 million year-over-year. #### Operational Metrics (Second Quarter 2026) Average Medicare Advantage membership grew by 48.7% year-over-year to 156,840 in the second quarter of 2026, up from 105,494. Total Medicare Advantage membership at June 30, 2026, was 157,309, compared to 106,323 at June 30, 2025. #### Revenue and Costs (Second Quarter 2026) Total revenues for the second quarter of 2026 were $743.2 million, an increase of 55.6% from $477.6 million in the same period last year. Insurance revenue specifically grew by 57.0% to $737.8 million from $469.8 million. Insurance net medical claims incurred increased by 56.1% to $615.4 million from $394.2 million. The Insurance Benefits Expense Ratio (BER) improved by 80 basis points, decreasing to 87.6% from 88.4% year-over-year. Salaries and benefits plus General and administrative expenses (SG&A) increased by 13.3% to $124.4 million from $109.8 million. Adjusted SG&A rose by 35.9% to $112.1 million from $82.5 million. As a percentage of Total revenues, Adjusted SG&A decreased by 220 basis points to 15.1% from 17.3%. #### Cash and Investments (As of June 30, 2026) Total cash, cash equivalents, and investments stood at $443.0 million as of June 30, 2026, an increase of 13.8% from $389.3 million as of June 30, 2025. ### Six Months Ended June 30, 2026 Financial Highlights For the six months ended June 30, 2026, Clover Health Investments, Corp. reported a GAAP Net Income of $55.3 million, compared to a net loss of - $11.9 million in the prior year period. Total revenues increased by 58.8% to $1,492.4 million from $939.9 million. Consolidated Gross Profit rose by 49.9% to $312.5 million from $208.5 million. Adjusted EBITDA increased by 89.3% to $81.2 million from $42.9 million. Adjusted Net income was $80.1 million, an increase of 90.7% from $42.0 million. #### Cash Flow (Six Months Ended June 30, 2026) Net cash provided by operating activities was $133.1 million for the six months ended June 30, 2026, a significant turnaround from net cash used in operating activities of - $10.9 million in the prior year period. Net cash used in investing activities was - $5.1 million, compared to net cash provided by investing activities of $44.5 million. Net cash used in financing activities was - $7.4 million, an improvement from - $39.5 million. ### Full Year 2026 Guidance Clover Health Investments, Corp. improved its full-year 2026 guidance across all metrics. The company now expects average Medicare Advantage membership to be between 156,000 and 158,000, representing 47% growth year-over-year at the midpoint, and projects total revenues between $2.92 billion and $3.00 billion, indicating 54% growth year-over-year at the midpoint. Consolidated Gross Profit is anticipated to range from $525 million to $555 million, representing 52% growth year-over-year at the midpoint, with Adjusted EBITDA expected to be profitable between $70 million and $85 million, and GAAP Net Income forecasted to be between $20 million and $35 million. The company also expressed increasing confidence for its 2027 outlook, supported by strong cohort development, continued clinical engagement, and the added flexibility of a 4.5 Star payment year. ### Related Stocks - [CLOV.US](https://longbridge.com/en/quote/CLOV.US.md) ## Related News & Research - [Clover Health releases transcript of 2Q26 supplemental Q&A on earnings call](https://longbridge.com/en/news/296533818.md) - [SelectQuote Q4 2026 Earnings Preview](https://longbridge.com/en/news/296823343.md) - [NAPC Defense announces availability of fiscal 2026 Form 10-K report](https://longbridge.com/en/news/296821941.md) - [Xcel Energy sets BRL 0.26 per unit distribution for payment Oct. 26, 2026](https://longbridge.com/en/news/296646864.md) - [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**